INDSWFTLAB - Ind-Swift Labs.
📢 Recent Corporate Announcements
Ind-Swift Laboratories has been awarded the EcoVadis Silver Medal for its Global Business Unit (GBU), placing it among the top 15% of companies assessed globally for sustainability. The GBU is a 100% Export Oriented Unit, and this certification is a key prerequisite for securing partnerships with multinational pharmaceutical companies in regulated markets. The assessment evaluates the company across 200+ industries on environment, ethics, and labor rights. This achievement, alongside existing ISO and SMETA certifications, strengthens the company's global credibility and competitive positioning.
- Achieved EcoVadis Silver Medal, placing the company in the top 15% of global organizations assessed.
- The certification specifically covers the 100% Export Oriented Global Business Unit (GBU) located in Punjab.
- Evaluation methodology aligns with UN Global Compact Principles, ILO Conventions, and ISO 26000 guidelines.
- Reinforces a robust compliance framework including ISO 14001, 45001, 27001, and 37001 certifications.
- Enhances eligibility for international tenders and supply chain partnerships with global pharmaceutical majors.
Ind-Swift Laboratories has announced the lapse of 65,00,000 fully convertible warrants after the allottee, Saral Incorporated VCC Sub Fund 1, failed to exercise the conversion option within the 18-month deadline. As a result, the company has forfeited the 25% upfront subscription amount, totaling ₹19,66,25,000. While the company retains this cash as a capital reserve, it will miss out on the remaining 75% of the capital infusion originally expected from these specific warrants. Out of the original 2.6 crore warrants issued in August 2024, 1.95 crore were successfully converted into equity.
- 65,00,000 warrants lapsed due to non-exercise by a non-promoter investor
- Company forfeited ₹19.66 crore (25% of the issue price of ₹121 per warrant)
- Total preferential issue consisted of 2.6 crore warrants, of which 75% were converted
- No change in current paid-up equity share capital resulting from this lapse
- The 18-month conversion period ended on February 28, 2026
Essix Biosciences Limited, a key promoter group entity, has converted 51,00,000 fully convertible warrants into equity shares of Ind-Swift Laboratories. The conversion was executed at an issue price of Rs 121 per share, resulting in a capital infusion of approximately Rs 61.71 crore. This transaction has increased the total promoter and promoter group holding from 39.50% to 43.06%. Such a move typically indicates strong promoter confidence in the company's future performance and financial health.
- Conversion of 51,00,000 warrants into equity shares by promoter entity Essix Biosciences Limited.
- The transaction value is approximately Rs 61.71 crore based on an allotment price of Rs 121 per share.
- Promoter group shareholding increased significantly from 39.50% to 43.06% post-allotment.
- Total paid-up equity share capital expanded from 8,16,11,558 to 8,67,11,558 shares of Rs 10 each.
Ind-Swift Laboratories Limited has scheduled a virtual one-on-one meeting with Seven Canyons Funds - Stock Pro Advisors. The meeting is slated for March 2, 2026, at 6:30 PM IST, which is after standard Indian market hours. This interaction is part of the company's routine investor engagement under SEBI Listing Obligations. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the discussion.
- One-on-one virtual meeting scheduled for Monday, March 2, 2026, at 06:30 P.M. IST.
- The meeting involves institutional investor Seven Canyons Funds - Stock Pro Advisors.
- Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
- Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the meet.
Ind-Swift Laboratories has approved the allotment of 51,00,000 equity shares following the conversion of warrants by the promoter group entity, Essix Biosciences Limited. The conversion was executed at an issue price of ₹121 per share, bringing in the balance subscription amount of approximately ₹46.28 crores. This transaction increases the company's total paid-up equity share capital to ₹86.71 crores. The exercise of these warrants by the promoter group indicates strong internal confidence in the company's future performance.
- Allotment of 51,00,000 equity shares of ₹10 face value to Essix Biosciences Limited
- Conversion price of ₹121 per share resulting in a capital infusion of ₹46.28 crores
- Total paid-up equity capital increased to ₹86,71,15,580 divided into 8,67,11,558 shares
- Warrants were originally allotted on August 30, 2024, and have now been fully converted
Ind-Swift Laboratories is investing ₹400 million to upgrade its Samba facility to meet EU-GMP and PIC/S standards, targeting high-margin regulated markets like Europe and Australia. The company expects this upgrade to more than double the unit's revenue from ₹360 million to ₹750-800 million by FY 2027-28. Furthermore, margins are projected to nearly double from 10% to 18-20% following the shift to regulated exports. This strategic move follows the company's transition to a net debt-free organization after divesting its API business.
- Capital investment of ₹400 million to achieve EU-GMP and PIC/S compliance at the Samba unit.
- Unit revenue projected to grow from ₹360 million to ₹750-800 million by FY 2027-28.
- Anticipated bottom-line margin expansion from 10% to 18-20% post-upgradation.
- Plans to file 15-20 molecules across Europe, UK, Australia, Canada, and South Africa.
- Company has transitioned to a net debt-free status following a ₹1,650 crore divestment of its API business.
Ind-Swift Laboratories has successfully transitioned into a pure-play formulations company following a ₹1,650 Cr divestment of its API business, making the entity net debt-free. For Q3 FY26, the company reported a 22.60% QoQ increase in Net Profit, driven by improved operational efficiencies and a 6.60% rise in Operating EBITDA. The company is targeting a revenue doubling by FY29, supported by high-margin segments like Ethical formulations (76% Gross Margin) and a strategic partnership with Viatris starting in FY27. With a consolidated structure following the merger of Ind-Swift Ltd, the entity is now focused on high-growth export markets and domestic chronic therapies.
- Completed ₹1,650 Cr divestment of API & CRAMS business to become a net debt-free entity
- Reported 22.60% QoQ growth in Net Profit (PAT) for Q3 FY26 with EBITDA margins expanding by 48 bps
- Targeting to double revenue by FY29 from a current base of ₹550 Cr, focusing on high-margin ethical formulations (76% GM)
- Strategic partnership with Viatris expected to deliver a ₹200 Cr revenue impact starting in FY27
- Consolidated portfolio includes 1,915+ global dossiers and 520+ approvals across 85+ countries post-merger
Ind-Swift Laboratories Limited has announced a one-on-one investor meeting with NV Alpha Fund Management scheduled for February 5, 2026. The meeting will be conducted virtually at 12:30 P.M. IST to discuss the company's performance and outlook. This interaction is part of the company's routine engagement with institutional investors under SEBI (LODR) Regulations. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session.
- One-on-one virtual meeting scheduled with NV Alpha Fund Management.
- The meeting is set for Thursday, February 5, 2026, at 12:30 P.M. IST.
- Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed.
- The schedule is subject to change based on exigencies from either party.
Ind-Swift Laboratories has confirmed that there is no deviation or variation in the utilization of funds raised through its preferential issue of convertible warrants. As of December 31, 2025, the company has raised Rs 209.41 crores out of a total issue size of Rs 314.60 crores. A total of Rs 208.95 crores has been deployed toward business expansion, working capital, and general corporate purposes. The statement has been reviewed by the Audit Committee and monitored by CARE Ratings Limited, ensuring transparency in capital allocation.
- Reported nil deviation in the utilization of funds raised through preferential issue of convertible warrants.
- Total amount raised as of Dec 31, 2025, stands at Rs 209.41 crores against a total issue size of Rs 314.60 crores.
- Cumulative funds utilized amount to Rs 208.95 crores, with Rs 70.48 crores spent on business expansion.
- Full allocation of Rs 39.60 crores for working capital and Rs 75.00 crores for general corporate purposes has been completed.
- The utilization report was monitored by CARE Ratings Limited and reviewed by the company's Audit Committee.
Ind-Swift Laboratories reported a strong Q3 FY26 performance with a net profit of ₹1,074.18 Lakhs, marking a significant turnaround from a loss of ₹86.19 Lakhs in the same quarter last year. Revenue from operations grew by 30.5% year-on-year to ₹158.58 Crores. The company also announced a strategic management reshuffle, splitting the Managing Director role into dedicated Domestic and Global operations to drive specialized growth. Additionally, the board approved the re-designation of Mr. Navrattan Munjal as Chairman and Whole-Time Director.
- Net Profit for Q3 FY26 stood at ₹10.74 Crores compared to a loss of ₹0.86 Crores in Q3 FY25.
- Revenue from operations increased to ₹158.58 Crores, up from ₹121.52 Crores in the previous year's corresponding quarter.
- Management restructuring effective Feb 1, 2026, creates dedicated MD roles for Domestic (Himanshu Jain) and Global (Sahil Munjal) operations.
- Finance costs for the quarter decreased to ₹8.36 Crores from ₹10.03 Crores in the year-ago period.
- Earnings Per Share (EPS) improved to ₹1.27 for the quarter, up from ₹1.05 in the preceding quarter.
Ind-Swift Laboratories Limited (INDSWFTLAB) has announced a one-on-one investor meeting with Omkara Capital scheduled for January 23, 2026. The meeting will take place virtually at 3:30 P.M. IST to discuss the company's performance and outlook. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during the session. This interaction is part of the company's regular engagement with institutional investors under SEBI regulations.
- One-on-one investor meeting scheduled with Omkara Capital on January 23, 2026.
- The meeting is set to commence at 3:30 P.M. IST via virtual mode.
- Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.
- Company confirms that no unpublished price-sensitive information will be disclosed.
Ind-Swift Laboratories has completed a major strategic transformation by divesting its API and CRAMS business for ₹1,650 crore, effectively becoming a net debt-free entity. The company has merged with Ind-Swift Limited to create a unified pure-play formulations platform with a current revenue base of ₹550 crore. Management aims to double this revenue by FY29, supported by high-margin segments like Ethical formulations (76% gross margin) and a strategic partnership with Viatris starting in FY27. The company now focuses on high-growth exports across 85+ countries with a robust pipeline of 1,915+ dossiers.
- Divested API & CRAMS business for ₹1,650 Cr to become a Net Debt Free entity
- Merged Ind-Swift Limited into ISLL to consolidate operations into a pure-play formulations platform
- Targeting to double revenue by FY29 from the current base of ₹550 Cr
- High-margin profile with Ethical formulations at 76% GM and Own-Brand at 51% GM
- Strategic Viatris partnership expected to contribute ₹200 Cr impact starting in FY27
Ind-Swift Laboratories has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate, issued by Registrar and Share Transfer Agent Alankit Assignments Ltd., confirms that physical share certificates received for dematerialization were processed and cancelled. This filing ensures that the depository's name has been correctly substituted in the company's records as the registered owner. This is a standard procedural disclosure required for all listed entities in India.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Confirmation provided by Registrar and Share Transfer Agent, Alankit Assignments Ltd.
- Physical share certificates received for dematerialization were duly mutilated and cancelled.
- Depository names substituted in records as the registered owners for the processed shares.
Ind-Swift Laboratories Limited has announced the closure of its trading window effective January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the declaration of the company's un-audited standalone and consolidated financial results for the quarter ending December 31, 2025. The window will remain closed for all promoters, directors, and designated persons until 48 hours after the results are made public. This is a standard regulatory procedure followed by listed companies every quarter to prevent insider trading.
- Trading window closure effective from January 1, 2026.
- Closure is related to the financial results for the quarter ended December 31, 2025.
- Restricts trading for promoters, directors, KMPs, and designated persons.
- Window to reopen 48 hours after the announcement of financial results.
- Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Ind-Swift Laboratories has disclosed the transmission of 2,32,057 equity shares, representing approximately 0.28% of the company, to the legal heirs of the late Mrs. Neera Mehta. The shares were credited to a joint demat account held by Mr. Rishav Mehta, Ms. Ishav Mehta, and Mr. Daksh Mehta following regulatory clearances related to a prior amalgamation. This is an inter-se transfer within the promoter group and does not result in any change to the aggregate promoter shareholding. The transaction is exempt from open offer requirements under SEBI (SAST) Regulations.
- Transmission of 2,32,057 equity shares (0.28% stake) to legal heirs of Late Mrs. Neera Mehta
- Shares were previously pending credit due to regulatory approvals following the amalgamation of Ind-Swift Limited
- Joint holding of the legal heirs increased from 2,49,000 (0.31%) to 4,81,057 (0.59%) shares
- Aggregate shareholding of the Promoter and Promoter Group remains unchanged
- Transaction conducted under exemption provided by Regulation 10(1)(g) of SEBI SAST Regulations
Financial Performance
Revenue Growth by Segment
Consolidated revenue for FY25 was INR 549.65 Cr, representing a 55.2% decrease from INR 1,227.32 Cr in FY24. Standalone turnover dropped 67.1% from INR 1,672.57 Cr to INR 549.65 Cr. These figures are not directly comparable due to the slump sale of the API and CRAMS business in March 2024 and the subsequent merger with Ind-Swift Limited (formulations).
Geographic Revenue Split
Exports contributed INR 399.23 Cr, accounting for 72.6% of total revenue in FY25. This is a significant decrease from INR 1,339.29 Cr in FY24, following the divestment of the API business which was export-heavy.
Profitability Margins
The company reported a Net Profit of INR 256.09 Cr in FY25, a 52.2% decrease from INR 536.18 Cr in FY24. The Net Profit margin for FY25 stood at 46.6%, though this is impacted by the structural changes from the slump sale and merger. Return on Equity (ROE) was 32.06%.
EBITDA Margin
Return on Capital Employed (ROCE) was reported at 22.00% for FY25. Core profitability metrics were significantly altered by the transition from an API-focused model to a formulations-focused model post-merger.
Capital Expenditure
R&D capital expenditure was INR 0.05 Cr out of a total R&D spend of INR 14.79 Cr in FY25. Standalone Property, Plant, and Equipment (PPE) increased from INR 258.84 Cr in March 2025 to INR 270.21 Cr by September 2025.
Credit Rating & Borrowing
CARE Ratings placed the company on 'Rating Watch with Developing Implications' following the slump sale. The rating is supported by improved solvency but constrained by high debt repayment obligations in the medium term and significant intergroup transactions.
Operational Drivers
Capacity Expansion
The company is expanding its product pipeline with new instruments and world-class technologies, though specific capacity figures in MT or units were not disclosed.
Manufacturing Efficiency
Manufacturing facilities are GMP compliant and ISO 9001:2008 certified, ensuring adherence to international quality standards for export markets.
Strategic Growth
Growth Strategy
The company is pursuing a new business model by integrating Ind-Swift Limited (formulations) with Ind-Swift Laboratories Limited. This strategy aims to capture higher margins in the finished dosage forms market and leverage established client relations from the promoters' 30+ years of industry experience.
Products & Services
Pharmaceutical formulations, medicines, and off-patent products. Previously included APIs and CRAMS services prior to the March 2024 slump sale.
Brand Portfolio
Ind-Swift.
New Products/Services
The company is developing non-infringing formulations and processes, with a focus on off-patent products to build a robust pipeline post-expansion.
Market Expansion
Targeting regulated and semi-regulated markets through its US subsidiary, Ind-Swift Laboratories Inc., which recorded sales of INR 23.76 Cr in FY25.
Strategic Alliances
Maintains a Joint Venture, Indis Healthcare LLP, which achieved a turnover of INR 13.71 Cr in FY25. The company also focuses on collaborative research and strategic alliances to enhance its R&D network.
External Factors
Industry Trends
The pharmaceutical industry is shifting toward specialized formulations and off-patent products. Ind-Swift is positioning itself by divesting its commodity API business to focus on higher-value formulation manufacturing and R&D.
Competitive Landscape
Competes in the global formulations and generic drug market, facing pressure from both domestic Indian manufacturers and international pharmaceutical firms.
Competitive Moat
The company's moat is built on regulatory approvals (USFDA, KFDA, PMDA) and a 30-year track record. These are sustainable as long as GMP compliance is maintained and R&D continues to produce non-infringing processes.
Macro Economic Sensitivity
High sensitivity to foreign exchange fluctuations as 72.6% of revenue is export-based, while foreign exchange outgo was only INR 27.54 Cr in FY25.
Consumer Behavior
Increasing demand for affordable generic medicines and off-patent formulations globally supports the company's strategic shift.
Geopolitical Risks
Trade barriers or regulatory changes in the US, Korea, or Japan could disrupt export operations, which are critical to the company's current revenue structure.
Regulatory & Governance
Industry Regulations
Operations are governed by GMP (Good Manufacturing Practices), ISO 9001:2008, and international standards from the USFDA, KFDA (Korea), and PMDA (Japan). Compliance is mandatory for maintaining export market access.
Taxation Policy Impact
The company maintains a standalone Deferred Tax Asset of INR 44.63 Cr as of September 2025.
Legal Contingencies
The Secretarial Audit for FY25 confirmed compliance with the Companies Act 2013 and SEBI regulations. No specific pending court case values were disclosed in the provided documents.
Risk Analysis
Key Uncertainties
The primary uncertainty is the long-term margin sustainability of the new formulations-focused business model following the exit from the API segment. The US subsidiary's net loss of INR 5.88 Cr also presents a performance risk.
Geographic Concentration Risk
72.6% of revenue is concentrated in export markets, making the company vulnerable to international regulatory shifts.
Third Party Dependencies
Significant dependency on intergroup transactions as noted by credit rating agencies, which could impact fiscal transparency and operational independence.
Technology Obsolescence Risk
Risk of product obsolescence is mitigated by an R&D investment of 2.9% of turnover, focusing on new product pipelines and world-class technologies.
Credit & Counterparty Risk
Standalone trade receivables stood at INR 168.53 Cr as of September 30, 2025, representing approximately 30.6% of annual turnover, indicating significant credit exposure.